Cite
HARVARD Citation
Shi, X. et al. (2022). Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma. American journal of hematology. 97 (5), pp. 537-547. [Online].